Ownership and insider activity for Humacyte, Inc. (HUMA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs).
Price
| Price | $0.57 |
| Market Cap | $96M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $93.7M | $39.9M | $217.5M | $149.8M | $80.4M | $44.9M | $50.5M |
| Short-term Investments | 0 | 0 | $8.0M | $2.1M | 0 | 0 | 0 |
| Receivables | $601000 | $113000 | $176000 | $31000 | 0 | 0 | $441000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | $13.6M |
| Total Current Assets | $95.0M | $41.4M | $229.3M | $154.2M | $83.3M | $47.9M | $67.8M |
| Property, Plant & Equipment | $73.7M | $65.2M | $57.2M | $50.1M | $44.1M | $38.6M | $47.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $168.7M | $106.7M | $286.5M | $204.3M | $128.2M | $137.9M | $116.4M |
| Accounts Payable | $3.3M | $2.3M | $2.1M | $1.6M | $6.5M | $4.5M | $5.4M |
| Short-term Debt | $1.5M | $2.5M | 0 | $8.6M | 0 | 0 | 0 |
| Total Current Liabilities | $10.8M | $11.2M | $11.1M | $19.6M | $18.4M | $20.0M | $18.4M |
| Long-term Debt | 0 | $822000 | $27.4M | $20.3M | $38.6M | 0 | $35.4M |
| Total Liabilities | $36.5M | $36.0M | $164.4M | $87.4M | $114.7M | $190.5M | $113.3M |
| Retained Earnings | -$321.6M | -$388.1M | -$414.6M | -$426.5M | -$537.3M | -$686.0M | -$726.8M |
| Total Equity | $132.2M | $70.7M | $122.2M | $116.9M | $13.5M | -$52.7M | $3.1M |
| Total Debt | $28.7M | $28.9M | $51.2M | $50.1M | $57.5M | $16.5M | $64.8M |
| Net Debt | -$65.0M | -$11.1M | -$174.3M | -$101.8M | -$23.0M | -$28.4M | $14.3M |
| Working Capital | $84.1M | $30.2M | $218.3M | $134.6M | $64.8M | $27.9M | $49.4M |
Financial Health
| Debt / Equity | 2.12 |
| Current Ratio | 6.21 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -10.46 |
Profitability
| Return on Equity | -938.20% |
| Return on Invested Capital | -89.17% |
| Return on Assets | -70.05% |
| Gross Margin | -666.81% |
| Operating Margin | -5240.78% |
| Net Margin | -4560.82% |
Related companies: ACHV · ARCT · AVIR · FHTX · IMRX · NAUT · SGMT
Explore sector: Healthcare · Biotechnology
More sections of HUMA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks